UY36145A - Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer - Google Patents

Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer

Info

Publication number
UY36145A
UY36145A UY0001036145A UY36145A UY36145A UY 36145 A UY36145 A UY 36145A UY 0001036145 A UY0001036145 A UY 0001036145A UY 36145 A UY36145 A UY 36145A UY 36145 A UY36145 A UY 36145A
Authority
UY
Uruguay
Prior art keywords
compounds
salts
cancer
thiadiazole
treatment
Prior art date
Application number
UY0001036145A
Other languages
English (en)
Inventor
Chukuemeka Tennyson Ekwuru
Charles Mark
Johannes Wilhelmus Maria Nissink
Piotr Antoni Raubo
Jon James Winter-Holt
Maurice Raymond Verschoyle Finlay
Original Assignee
Cancer Rec Tech Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Astrazeneca Ab filed Critical Cancer Rec Tech Ltd
Publication of UY36145A publication Critical patent/UY36145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente se refiere a los compuestos de la Fórmula (I): y a las sales de ellos adecuadas para usos farmacéuticos, donde Q, R, R1 y R2 poseen cualesquiera de los significados que se definen en la presente memoria. También se refiere al uso de dichos compuestos y sales de los mismos para tratar o prevenir las enfermedades mediadas por GLS1, incluyendo el cáncer. Asimismo se refiere a formas cristalinas de los compuestos de la Fórmula (I) y sales de ellos adecuadas para usos farmacéuticos; a composiciones farmacéuticas que comprenden dichos compuestos y sales
UY0001036145A 2014-05-30 2015-05-28 Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer UY36145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1409624.2A GB201409624D0 (en) 2014-05-30 2014-05-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
UY36145A true UY36145A (es) 2016-01-08

Family

ID=51214473

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036145A UY36145A (es) 2014-05-30 2015-05-28 Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer

Country Status (39)

Country Link
US (2) US10040788B2 (es)
EP (1) EP3148994B1 (es)
JP (1) JP6538830B2 (es)
KR (1) KR20170005875A (es)
CN (1) CN106795150B (es)
AP (1) AP2016009578A0 (es)
AR (1) AR100694A1 (es)
AU (1) AU2015265703B2 (es)
BR (1) BR112016028002B1 (es)
CA (1) CA2949598C (es)
CL (1) CL2016003074A1 (es)
CR (1) CR20160558A (es)
CY (1) CY1120836T1 (es)
DK (1) DK3148994T3 (es)
DO (1) DOP2016000308A (es)
EA (1) EA030937B1 (es)
ES (1) ES2688396T3 (es)
GB (1) GB201409624D0 (es)
GT (1) GT201600250A (es)
HR (1) HRP20181490T1 (es)
HU (1) HUE039879T2 (es)
IL (1) IL249020B (es)
LT (1) LT3148994T (es)
MX (1) MX2016015738A (es)
MY (1) MY192861A (es)
NI (1) NI201600176A (es)
NZ (1) NZ726790A (es)
PE (1) PE20170148A1 (es)
PH (1) PH12016502394A1 (es)
PL (1) PL3148994T3 (es)
PT (1) PT3148994T (es)
RS (1) RS57876B1 (es)
SG (1) SG11201609880QA (es)
SI (1) SI3148994T1 (es)
SV (1) SV2016005330A (es)
TN (1) TN2016000511A1 (es)
TW (1) TWI693220B (es)
UY (1) UY36145A (es)
WO (1) WO2015181539A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) * 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201730188A (zh) * 2015-11-30 2017-09-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
JP7275053B2 (ja) * 2017-06-13 2023-05-17 メッドシャイン ディスカバリー インコーポレイテッド Ｇｌｓ１阻害剤としての化合物
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
CN112888686B (zh) * 2018-10-16 2022-04-19 南京明德新药研发有限公司 噻二唑衍生物及其作为gls1抑制剂的应用
JP7453989B2 (ja) * 2019-03-05 2024-03-21 アストラゼネカ・アクチエボラーグ 抗癌剤として有用な縮合三環式化合物
CN117003745A (zh) * 2023-07-20 2023-11-07 南京市第一医院 Gls1/hdac双靶点抑制剂及其合成方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2012170664A2 (en) 2011-06-10 2012-12-13 President And Fellows Of Harvard College Methods of cancer treatment and prevention through the modulation of sirt4 activity
SG11201402305WA (en) * 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
ES2690829T3 (es) * 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
MX2015005963A (es) 2012-11-16 2015-09-16 Calithera Biosciences Inc Inhibidores heterociclicos de glutaminasa.
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105283182A (zh) 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症

Also Published As

Publication number Publication date
MX2016015738A (es) 2017-02-27
BR112016028002A2 (es) 2017-08-22
PT3148994T (pt) 2018-10-22
GB201409624D0 (en) 2014-07-16
US20180305349A1 (en) 2018-10-25
US20170197954A1 (en) 2017-07-13
HRP20181490T1 (hr) 2019-01-11
CA2949598A1 (en) 2015-12-03
DOP2016000308A (es) 2017-03-15
SV2016005330A (es) 2017-06-07
MY192861A (en) 2022-09-13
JP2017516859A (ja) 2017-06-22
DK3148994T3 (en) 2018-10-08
KR20170005875A (ko) 2017-01-16
SI3148994T1 (sl) 2018-12-31
WO2015181539A1 (en) 2015-12-03
AR100694A1 (es) 2016-10-26
PH12016502394A1 (en) 2017-02-20
AP2016009578A0 (en) 2016-11-30
TN2016000511A1 (en) 2018-04-04
SG11201609880QA (en) 2016-12-29
TWI693220B (zh) 2020-05-11
IL249020A0 (en) 2017-01-31
US10294221B2 (en) 2019-05-21
EA030937B1 (ru) 2018-10-31
CN106795150A (zh) 2017-05-31
CA2949598C (en) 2022-08-09
CR20160558A (es) 2017-09-01
US10040788B2 (en) 2018-08-07
NZ726790A (en) 2017-11-24
PE20170148A1 (es) 2017-04-05
EP3148994B1 (en) 2018-07-11
LT3148994T (lt) 2018-11-26
IL249020B (en) 2020-11-30
NI201600176A (es) 2017-08-25
EA201692260A1 (ru) 2017-06-30
PL3148994T3 (pl) 2019-04-30
EP3148994A1 (en) 2017-04-05
JP6538830B2 (ja) 2019-07-03
CN106795150B (zh) 2019-10-15
AU2015265703B2 (en) 2017-12-07
GT201600250A (es) 2019-06-10
ES2688396T3 (es) 2018-11-02
RS57876B1 (sr) 2018-12-31
AU2015265703A1 (en) 2016-12-15
CY1120836T1 (el) 2019-12-11
CL2016003074A1 (es) 2017-04-28
BR112016028002B1 (pt) 2022-09-27
TW201609720A (zh) 2016-03-16
HUE039879T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CO2018002060A2 (es) Compuestos farmacéuticos
CO2017006214A2 (es) Derivados de quinazolina utilizados para tratar el vih
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY36126A (es) ?compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr?.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CR20170157A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial
CL2017002229A1 (es) Inhibidores de bace1.
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220620